Tag: FDA bioequivalence
Narrow Therapeutic Index Drugs: Stricter Bioequivalence Requirements Explained
Narrow therapeutic index drugs require stricter bioequivalence standards to ensure patient safety. Learn how the FDA, EMA, and Health Canada differ in their rules, why generics are harder to make, and what this means for your treatment.
Read more
Recent Advances in Bioequivalence Testing: Emerging Technologies
Recent advances in bioequivalence testing are transforming how generic drugs are approved. AI tools like BEAM, virtual bioequivalence models, and advanced imaging are replacing outdated clinical trials, cutting costs and timelines while improving accuracy.
Read more